Characteristics of patients enrolled in IV, V, VI, and VIII MRC Multiple Myeloma trials
Trial, dates (patient ages), and induction treatment . | No. patients . | Median OS, y . | Median DP, y . | IgG, % . | IgA, % . | LCO, % . |
|---|---|---|---|---|---|---|
| IV, 1980-1982 (under 80 y) | ||||||
| MP | 254 | 2.3 | 1.1 | 59 | 29 | 12 |
| MPV | 251 | 2.2 | 1.5 | 57 | 24 | 19 |
| V, 1982-1986 (under 75 y) | ||||||
| C-weekly-plts < 80 | 58 | 1.8 | 1.7 | 53 | 28 | 19 |
| M7 | 291 | 2.0 | 1.4 | 56 | 29 | 15 |
| ABCM | 293 | 2.7 | 1.6 | 56 | 27 | 17 |
| VI (under 75 y) | ||||||
| 1986-1991 | ||||||
| HDM (M140) | 12 | 2.5 | 2.5 | 59 | 33 | 8 |
| HDMP | 14 | 5.0 | 1.9 | 71 | 29 | 0 |
| ABCM | 322 | 2.7 | 1.5 | 58 | 28 | 14 |
| ABCM-P | 328 | 2.5 | 1.4 | 58 | 29 | 13 |
| 1991-1993 | ||||||
| NR ABCM | 271 | 2.6 | 1.4 | 58 | 28 | 14 |
| VIII, 1993-2002 (at least 65 y, or under 65 y*) | ||||||
| ABCM to plateau | 135 | 3.1 | 1.4 | 69 | 25 | 6 |
| ABCM ×3 then C-weekly | 140 | 3.1 | 1.5 | 56 | 36 | 8 |
| NR | 223 | 1.2 | 1.3 | 63 | 24 | 13 |
| Total | 2592 | NA | NA | 58 | 28 | 14 |
Trial, dates (patient ages), and induction treatment . | No. patients . | Median OS, y . | Median DP, y . | IgG, % . | IgA, % . | LCO, % . |
|---|---|---|---|---|---|---|
| IV, 1980-1982 (under 80 y) | ||||||
| MP | 254 | 2.3 | 1.1 | 59 | 29 | 12 |
| MPV | 251 | 2.2 | 1.5 | 57 | 24 | 19 |
| V, 1982-1986 (under 75 y) | ||||||
| C-weekly-plts < 80 | 58 | 1.8 | 1.7 | 53 | 28 | 19 |
| M7 | 291 | 2.0 | 1.4 | 56 | 29 | 15 |
| ABCM | 293 | 2.7 | 1.6 | 56 | 27 | 17 |
| VI (under 75 y) | ||||||
| 1986-1991 | ||||||
| HDM (M140) | 12 | 2.5 | 2.5 | 59 | 33 | 8 |
| HDMP | 14 | 5.0 | 1.9 | 71 | 29 | 0 |
| ABCM | 322 | 2.7 | 1.5 | 58 | 28 | 14 |
| ABCM-P | 328 | 2.5 | 1.4 | 58 | 29 | 13 |
| 1991-1993 | ||||||
| NR ABCM | 271 | 2.6 | 1.4 | 58 | 28 | 14 |
| VIII, 1993-2002 (at least 65 y, or under 65 y*) | ||||||
| ABCM to plateau | 135 | 3.1 | 1.4 | 69 | 25 | 6 |
| ABCM ×3 then C-weekly | 140 | 3.1 | 1.5 | 56 | 36 | 8 |
| NR | 223 | 1.2 | 1.3 | 63 | 24 | 13 |
| Total | 2592 | NA | NA | 58 | 28 | 14 |
IgG, 1513 patients; IgA, 718 patients; LCO, 361 patients.
MP indicates melphalan, prednisolone; MPV, melphalan, prednisolone, vincristine; C-weekly plts, cyclophosphamide weekly for low platelets; M7, melphalan; ABCM, doxorubicin, carmustine, cyclophosphamide, melphalan; NR, nonrandomized; C-VAMP, cyclophosphamide, vincristine, doxorubicin, methylprednisolone; OS, overall survival; DP, duration of plateau; IgG, immunoglobulin G; IgA, immunoglobulin A; LCO, light chain only; and NA, not applicable.
If high-dose therapy (HDT) contraindicated.